GLPwatch
Trulicity for Polycystic ovary syndrome
dulaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCTrulicity (dulaglutide) is not FDA-approved for polycystic ovary syndrome (PCOS), and any use for this condition is off-label or investigational. Research in animals shows dulaglutide may improve hormonal and ovarian function, while a human trial compares dulaglutide plus a calorie-restricted diet to diet alone in women with PCOS.
AI summary of the sources below.
| Drug | Trulicity (dulaglutide) |
|---|---|
| Condition | Polycystic ovary syndrome |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Trulicity is not FDA-approved for polycystic ovary syndrome; the research below reflects investigational or off-label study only.
Research on dulaglutide for polycystic ovary syndrome (3)
- Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.
- Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.